» Articles » PMID: 35401669

Expanded CUG Repeat RNA Induces Premature Senescence in Myotonic Dystrophy Model Cells

Overview
Journal Front Genet
Date 2022 Apr 11
PMID 35401669
Authors
Affiliations
Soon will be listed here.
Abstract

Myotonic dystrophy type 1 (DM1) is a dominantly inherited disorder due to a toxic gain of function of RNA transcripts containing expanded CUG repeats (CUG). Patients with DM1 present with multisystemic symptoms, such as muscle wasting, cognitive impairment, cataract, frontal baldness, and endocrine defects, which resemble accelerated aging. Although the involvement of cellular senescence, a critical component of aging, was suggested in studies of DM1 patient-derived cells, the detailed mechanism of cellular senescence caused by CUG RNA remains unelucidated. Here, we developed a DM1 cell model that conditionally expressed CUG RNA in human primary cells so that we could perform a detailed assessment that eliminated the variability in primary cells from different origins. Our DM1 model cells demonstrated that CUG RNA expression induced cellular senescence by a telomere-independent mechanism. Furthermore, the toxic RNA expression caused mitochondrial dysfunction, excessive reactive oxygen species production, and DNA damage and response, resulting in the senescence-associated increase of cell cycle inhibitors p21 and p16 and secreted mediators insulin-like growth factor binding protein 3 (IGFBP3) and plasminogen activator inhibitor-1 (PAI-1). This study provides unequivocal evidence of the induction of premature senescence by CUG RNA in our DM1 model cells.

Citing Articles

New Horizons in Myotonic Dystrophy Type 1: Cellular Senescence as a Therapeutic Target.

Legare C, Berglund J, Duchesne E, Dumont N Bioessays. 2024; 47(3):e202400216.

PMID: 39723693 PMC: 11848125. DOI: 10.1002/bies.202400216.


A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.

Garcia-Puga M, Gerenu G, Bargiela A, Espinosa-Espinosa J, Mosqueira-Martin L, Sagartzazu-Aizpurua M Cells. 2024; 13(23).

PMID: 39682688 PMC: 11639790. DOI: 10.3390/cells13231939.


Fetal Brain MRI Findings in Myotonic Dystrophy and Considerations for Prenatal Genetic Testing.

Shear M, Penon-Portmann M, Shieh J, Glenn O, Thiet M, Chetty S Neurol Genet. 2024; 10(6):e200171.

PMID: 39444647 PMC: 11498903. DOI: 10.1212/NXG.0000000000200171.


Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1.

Conte T, Duran-Bishop G, Orfi Z, Mokhtari I, Deprez A, Cote I Nat Commun. 2023; 14(1):4033.

PMID: 37468473 PMC: 10356779. DOI: 10.1038/s41467-023-39663-3.


Individual transcriptomic response to strength training for patients with myotonic dystrophy type 1.

Davey E, Legare C, Planco L, Shaughnessy S, Lennon C, Roussel M JCI Insight. 2023; 8(14).

PMID: 37318869 PMC: 10443797. DOI: 10.1172/jci.insight.163856.

References
1.
Young M, Wakefield M, Smyth G, Oshlack A . Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 2010; 11(2):R14. PMC: 2872874. DOI: 10.1186/gb-2010-11-2-r14. View

2.
Grimberg A, Coleman C, Burns T, Himelstein B, Koch C, Cohen P . p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab. 2005; 90(6):3568-74. PMC: 4145590. DOI: 10.1210/jc.2004-1213. View

3.
Maier A, Westendorp R . Relation between replicative senescence of human fibroblasts and life history characteristics. Ageing Res Rev. 2009; 8(3):237-43. DOI: 10.1016/j.arr.2009.01.004. View

4.
Otero B, Poukalov K, Hildebrandt R, Thornton C, Jinnai K, Fujimura H . Transcriptome alterations in myotonic dystrophy frontal cortex. Cell Rep. 2021; 34(3):108634. PMC: 9272850. DOI: 10.1016/j.celrep.2020.108634. View

5.
Meinke P, Hintze S, Limmer S, Schoser B . Myotonic Dystrophy-A Progeroid Disease?. Front Neurol. 2018; 9:601. PMC: 6095001. DOI: 10.3389/fneur.2018.00601. View